---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003318"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:46:38.182362+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Impact BioMedical amends $12.86M promissory note with DSS; extends maturity to 2030

## Summary
- Funded principal balance increased to $12,859,328.60, including $1.23M in interest advances.
- Maturity extended to September 30, 2030; repayment in 60 monthly payments starting February 2024.
- Interest rate set at WSJ Prime + 0.50% (initially 9%); note is secured by blanket first lien on all assets.
- DSS, Inc., the majority shareholder of Impact, is the lender; no advance features remain under the note.
- Financial covenants require Impact to maintain positive net worth and limit additional indebtedness.

## SEC filing metadata
- accession: 0001493152-24-003318
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/0001493152-24-003318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003318
- JSON: https://secwatch.observer/filing/0001493152-24-003318.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003318.txt

## Key facts
- Material Agreements
  IMPACT BIOMEDICAL INC. amended Amended Revolving Promissory Note dated March 1, 2023 with DSS, Inc. valued at Principal balance of $12,859,328.60; maturity extended to September 30, 2030; WSJ Prime + 0.50% floa (effective 2024-01-18).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: DSS, Inc.
  - Value: Principal balance of $12,859,328.60; maturity extended to September 30, 2030; WSJ Prime + 0.50% floa
  - Effective: 2024-01-18
  source text: Effective January 18, 2024, DSS, Inc., a New York corporation ("DSS") and Impact BioMedical, Inc., a Nevada corporation ("Impact") entered into an amendment to the revolving promissory note dated March 1, 2023 (the "Original Note"), whereby DSS loaned Impact an original amount of up to $12,000,000 (the "Loan").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1834105/000149315224003318/0001493152-24-003318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.